Medicamen Biotech Limited · NSE:MEDICAMEQ
Medicamen Biotech — Investor Presentation (December 2021)
33 slides from Medicamen Biotech's investor presentation, Dec 4, 2021
Slide 1: Investor presentation filing letter to BSE and NSE
MEDICAMEN Biotech Limited Mme} Regd. & Corp. Office: Tel.: 011 - 47589500-51 (50 Lines), 1506, Chiranjiv Tower, E-mail: info@medicamen.com 43, Neha Place, Web: www.medicamen.com New Delhi - 110019 (INDIA) CIN No.: L74899DL1993PLC056594 Ref: STEX/IM/BSE/2021-22 Date: December 04, 2021 BSE Limited Nat
Slide 2: Shivalik Rasayan Ltd Corporate Presentation
Agrochemicals Pharmaceuticals Speciality Chemicals & Intermediates Shivalik Rasayan Ltd C O R P O R AT E P R E S E N TAT I O N
Slide 3: Vision
Vision “Improving health through offering innovative products” by leveraging R&D expertise in following three verticals: o Agro Chemicals o Pharmaceuticals o Speciality Chemicals Confidential 2
Slide 4: Contents
Contents Corporate Portfolio & Pipeline R&D and Strategy Overview Manufacturing & Plans Confidential 3
Slide 5: Who are we??
Who are we?? Shivalik Rasayan Ltd (SRL) is a leading producer of Agrochemicals in India with a market cap of > $ 150 million and has recently expanded into Pharmaceuticals & Speciality Chemicals by investing > $ 40 million Leadership team of SRL has been accredited with successful turn around of sic
Slide 6: Business Overview
Business Overview R&D Center R&D Capabilities: Bhiwadi Chemical & Formulation Development, Analytical Research Agrochemicals Plant Dehradun Manufacturing Capabilities: API Plant Dahej Agro-chemicals, Speciality Chemicals, APIs, Dosage Forms Agro- & Speciality Chemicals Plant (to be ready in 2023) Da
Slide 7: Group Structure
Group Structure Shareholding as of June 30, 2021 Promoters SRL 52.92% 44.83% Public Public 47.08% 44.20% 10.97% Pharmadenica A/S, Denmark Shivalik Rasayan Ltd Medicamen Biotech Ltd (SRL) (MBL) Confidential 6
Slide 8: Milestones
Milestones 1 1 1981: Commences commercial production Medicamen Biotech Limited - Dehradun Agrochemical Plant 1996: Operations started - Bhiwadi FDF Plant (non-onco) 1980- 1980- Shivalik Rasayan Limited 99 1985: Company declared sick & 99 1998: WHO-GMP approval – Bhiwadi FDF Plant (non-onco) register
Slide 9: Road Ahead
Road Ahead Medicamen Biotech Limited Shivalik Rasayan Limited 1 • Targeted oncology FDF launch in India 2022 • Targeted start of FDF dossier filing in USA & Europe 1 2 • Targeted API facilty approvals by USFDA, EMEA 2022- • Targeted FDF (onco) facility approval by USFDA, EMEA • Start of new Agro- &
Slide 10: Our Leadership Team
Our Leadership Team The Executive Management team at SRL has an extensive global experience & subject matter expertise and is passionate about fulfilling the vision of the company Vimal Kumar Shrawat, PhD Managing Director Rahul Bishnoi Chairman Suresh Kumar Singh Akshay Kant Chaturvedi, PhD Rajesh
Slide 11: SRL Group Strengths At A Glance
SRL Group Strengths At A Glance > 500 #1 > 75 > 30 Employees Dimethoate Technical Product approvals in Regulatory Agency Scientists : 60 (& # 2 Malathion overseas markets* Approvals (including QA & QC : 150 Technical) WHO, Brazil)* ..... Pharmacists : 100 ..... producer in India ..... ..... >10 > 25
Slide 12: SRL Group Global Presence
SRL Group Global Presence Agrochemicals • Products available in India and key overseas markets Europe Under Registration CIS Dosage Forms: non-oncology South Asia Kazakhstan, Tajikistan • Our products are approved in more Afghanistan, than 30 countries and are supplied Caribbean Islands Bhutan, Sri
Slide 13: Contents
Contents Corporate Portfolio & Pipeline R&D and Strategy Overview Manufacturing & Plans Confidential 12
Slide 14: SRL Group Portfolio At A Glance
SRL Group Portfolio At A Glance Agrochemicals APIs 2 > 20 > 25 > 35 Products for which Products under Non-Oncology Oncology SRL is largest Indian development APIs APIs manufacturer ..... ..... ..... ..... Specialization in organophosphorus based insecticides & chemicals > 75 > 25 Non-Oncology Oncolo
Slide 15: Agrochemicals
Agrochemicals Insecticides Malathion Technical Dimethoate Technical Dinotefuran Technical Cyantraniliprole Technical Fipronil Technical Pymetrozine Technical Chlorantraniprole Technical Fungicides Prothioconazole Technical Azoxistrobin Technical Hexaconazole Technical Intermediates / Specialty Chemi
Slide 16: Oncology APIs & Dosage Forms
Oncology APIs & Dosage Forms Product selection criteria: * attractive market size * patent expiry launches * low competition Global Global S No Product API by SRL S No Product API by SRL Revenues* Revenues* 1 Carfilzomib Planned $ 1.1 b 1 Abiraterone Planned $ 3.2 b 2 Bortezomib Available $ 1.5 b 2
Slide 17: Non-Oncology APIs
Non-Oncology APIs Well thought after product strategy: • Products with attractive global revenues (> $ 1b) • Substantial expected revenues for SRL Development Completed Global # API Revenues* 1 Dimethyl Fumarate $ 4.9 b 2 Fingolimod $ 3.7 b 3 Pirfenidone $ 1.3 b Under Development (>20 APIs) # API #
Slide 18: Contents
Contents Corporate Portfolio & Pipeline R&D and Strategy Overview Manufacturing & Plans Confidential 17
Slide 19: R&D and Manufacturing At A Glance
R&D and Manufacturing At A Glance Dehradun Agrochemicals Plant 2 New Delhi Head Office Haridwar Unit-1: Non-onco FDF Plant 6 1 R&D Center Bhiwadi Unit-2: Onco FDF Plant 7 5 Non-Onco FDF Plant 4 API Plant Dahej Dahej 3 Agro- & Speciality Chem Plant Confidential 18
Slide 20: R&D Center Bhiwadi
1 R&D Center Bhiwadi Confidential 19
Slide 21: R&D Center Bhiwadi
1 R&D Center Bhiwadi • Highly experienced technical team (60 scientists & pharmacists) with multiple developments and patents to its credit • 12,000 sq ft premises with investment > Rs 30 crores • Equipped with best-in-class equipment and systems for development of technical, complex APIs & formulat
Slide 22: Agrochemicals Plant Dehradun
2 Agrochemicals Plant Dehradun • 1450 MT annual capacity • > 95% capacity utilization • 20 acres land with green surroundings Confidential 21
Slide 23: Agro & Speciality Chemicals Plant Dahej
3 Agro & Speciality Chemicals Plant Dahej • New greenfield plant in GIDC, Dahej, Gujarat • 50,000 m2 facility • Environmental clearance received from Ministry of Environment & Forests • Initially only one block planned for Insecticides & Fungicides: • Planned annual capacity: 3500 MT • Operation com
Slide 24: API Plant Dahej
4 API Plant Dahej Confidential 23 Confidential 23
Slide 25: API Plant Dahej
4 API Plant Dahej • Site area of 50,000 m2 including all production blocks, buildings, utilities* • Design complaint with best-in-class regulatory requirements (US, Europe, Japan) • 4 oncology & 4 non-oncology blocks planned: thereof 1 onco & 1 non- onco block presently operational • Robust GMP comp
Slide 26: Non-Onco Dosage Form Plant Bhiwadi
5 Non-Onco Dosage Form Plant Bhiwadi • cGMP compliant facility with 210,000 sq ft covered area • Product types: Tablets, Capsules, Dry Syrups, Liquid Orals, ORS • Separate sections: • Beta Lactam Orals • Non-Beta Lactam Orals • Iron & Folic Acid Orals • Liquid Orals Confidential 25
Slide 27: Non-Onco Dosage Form Plant Unit-1, Haridwar
6 Non-Onco Dosage Form Plant Unit-1, Haridwar • cGMP compliant facility with 32,000 sq ft covered area • Product types: Tablets, Ointments, Liquid Orals Confidential 26
Slide 28: Oncology FDF Plant Unit-2, Haridwar
7 Oncology FDF Plant Unit-2, Haridwar Confidential 27
Slide 29: Oncology FDF Plant Unit-2: Injectable Section
Lyophilizer Unit 7 Oncology FDF Plant Unit-2: Haridwar Injectable Section: • Capacity of 120 vials/min with flexibility of handling different vial sizes, integrated with Particle Monitoring System for non-viable particle counting (NVPC) SCADA: Sterile • 5.6 m2 with 6+1 radiant shelves Lyophilization
Slide 30: Oncology FDF Plant Unit-2: Oral Solid Dose Section
Tablet Compression in Isolator 7 Oncology FDF Plant Integrated Line FBD Unit-2: Haridwar Oral Solid Dose (OSD) Section: • Integrated Granulation line (Glatt , 30 Kg capacity) with WIP technology & interchangeable bowl size • Tablet compression & encapsulation with Isolators • Tablet coater with WIP
Slide 31: Contents
Contents Corporate Portfolio & Pipeline R&D and Strategy Overview Manufacturing & Plans Confidential 30
Slide 32: Development & Commercial Strategy
Development & Commercial Strategy • Development Plan: pegged on patent expiry launches for Technicals as well Pharmaceuticals wherever applicable • Portfolio Strategy: focused on (1) patent expiry launches, (2) difficult to produce products with low competition, (3) high value & low volume products
Slide 33: Contact Details
Contact Details Global Head Quarters: 1506 Chiranjiv Tower, 43 Nehru Place, New Delhi – 110019, India info@shivalikrasayan.com +91 11 47589500 Websites: www.shivalikrasayan.com www.medicamen.com Disclaimer: Except for the historical information contained herein, statements in this presentation and t
Medicamen Biotech — Investor Presentation (December 2021) on 6ix